Healthcare [ 13/13 ] | Biotechnology [ 127/164 ]
NASDAQ | Common Stock
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.
The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.
It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies.
The company was incorporated in 2016 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | -0.48 Increased by +54.72% | -1.05 Increased by +54.29% |
| Feb 22, 24 | -0.86 Decreased by -13.16% | -1.01 Increased by +14.85% |
| Nov 2, 23 | -1.22 Decreased by -193.85% | -1.21 Decreased by -0.83% |
| Aug 3, 23 | -1.45 Decreased by -150.00% | -1.20 Decreased by -20.83% |
| May 4, 23 | -1.06 Decreased by -127.53% | -0.87 Decreased by -21.84% |
| Feb 23, 23 | -0.76 Decreased by -119.39% | -0.39 Decreased by -94.87% |
| Nov 3, 22 | 1.30 Increased by +58.54% | -0.21 Increased by +719.05% |
| Aug 9, 22 | -0.58 Decreased by -226.09% | 0.10 Decreased by -680.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 56.38 M Increased by +20.69% | -65.28 M Increased by +53.69% | Decreased by -115.79% Increased by +61.63% |
| Dec 31, 23 | 16.79 M Decreased by -22.96% | -115.97 M Decreased by -14.14% | Decreased by -690.85% Decreased by -48.15% |
| Sep 30, 23 | -4.10 M Decreased by -101.10% | -163.41 M Decreased by -193.21% | Increased by +3.99 K% Increased by +8.35 K% |
| Jun 30, 23 | -12.72 M Increased by +70.20% | -194.78 M Decreased by -154.63% | Increased by +1.53 K% Increased by +754.38% |
| Mar 31, 23 | 46.71 M Decreased by -96.20% | -140.96 M Decreased by -127.18% | Decreased by -301.76% Decreased by -815.63% |
| Dec 31, 22 | 21.79 M Decreased by -97.31% | -101.60 M Decreased by -119.34% | Decreased by -466.30% Decreased by -818.88% |
| Sep 30, 22 | 371.43 M Increased by +261.62% | 175.31 M Increased by +58.76% | Increased by +47.20% Decreased by -56.10% |
| Jun 30, 22 | -42.69 M Decreased by -124.53% | -76.49 M Decreased by -223.75% | Increased by +179.20% Increased by +404.38% |